All In Biotech

Drug Trial Radar · NCT06148649

Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus

A Phase 2, Multicenter, Randomised, Paralleled, Placebo-controlled (Double-blind) and Active Drug-controlled (Open) Study to Investigate Efficacy and Safety of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 234 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

234

Actual

Start

Dec 10, 2023

Primary completion

Feb 27, 2025

Study completion Apr 23, 2025

Sponsor

Sponsor type
Industry
First posted
Nov 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, parallel, placebo- and active comparator-controlled phase 2 trial to evaluate the efficacy, safety, pharmacokinetics and immunogenicity in subjects with T2DM. Patients treated with diet and exercise alone, or in combination with stable metformin monotherapy (≥1500 mg/day or maximum tolerated dose ≥1000 mg/ day.), will be enrolled. Approximately 225 participants will be randomized. The study includes four stages: screening period (up to 2 weeks), lead-in period (2 weeks), treatment period (12 weeks) and safety follow-up period (3 weeks after treatment).

Conditions

  • Type 2 Diabetes

Interventions

  • HEC88473, Placebo, DulaglutideDrug

    T2DM subjects, receiving a weekly dose of HEC88473, placebo or dulaglutide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline of HbA1c at week 12Time frame: Baseline to week 12

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • Shijiazhuang People's Hospital

    Shijiazhuang, Hebei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.